CA3030841A1 - Multiple bi-specific binding domain constructs with different epitope binding to treat cancer - Google Patents

Multiple bi-specific binding domain constructs with different epitope binding to treat cancer Download PDF

Info

Publication number
CA3030841A1
CA3030841A1 CA3030841A CA3030841A CA3030841A1 CA 3030841 A1 CA3030841 A1 CA 3030841A1 CA 3030841 A CA3030841 A CA 3030841A CA 3030841 A CA3030841 A CA 3030841A CA 3030841 A1 CA3030841 A1 CA 3030841A1
Authority
CA
Canada
Prior art keywords
seq
group
bdc
cdr sequences
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3030841A
Other languages
English (en)
French (fr)
Inventor
Christopher Mehlin
Colin CORRENTI
James Olson
Roland B. WALTER
Ashok BANDARANAYAKE
George S. LASZLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CA3030841A1 publication Critical patent/CA3030841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3030841A 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer Abandoned CA3030841A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662362397P 2016-07-14 2016-07-14
US62/362,397 2016-07-14
US201762480230P 2017-03-31 2017-03-31
US62/480,230 2017-03-31
PCT/US2017/042264 WO2018014001A1 (en) 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer

Publications (1)

Publication Number Publication Date
CA3030841A1 true CA3030841A1 (en) 2018-01-18

Family

ID=60952209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030841A Abandoned CA3030841A1 (en) 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer

Country Status (6)

Country Link
US (1) US20190233534A1 (Direct)
EP (1) EP3484516A4 (Direct)
JP (1) JP2019532017A (Direct)
AU (1) AU2017297603A1 (Direct)
CA (1) CA3030841A1 (Direct)
WO (1) WO2018014001A1 (Direct)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218207A1 (en) * 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
MX419677B (es) * 2018-06-21 2025-01-14 Regeneron Pharma Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos
EP3898682A1 (en) * 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Tumor-targeted agonistic cd28 antigen binding molecules
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
MX2021012386A (es) * 2019-04-09 2022-01-18 Sanofi Sa Proteínas de union triespecíficas, métodos y usos de las mismas.
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
CN114423452A (zh) * 2019-06-27 2022-04-29 维西欧制药公司 用于调节髓系细胞炎性表型的抗lrrc25组合物和方法及其用途
WO2021202726A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
CN115335396A (zh) * 2020-03-31 2022-11-11 弗莱德哈钦森癌症中心 靶向cd33的嵌合抗原受体
WO2021202770A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Human anti-cd33 antibodies and uses thereof
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
AU2021369835A1 (en) * 2020-10-30 2023-06-01 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
PE20250740A1 (es) * 2021-02-02 2025-03-13 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3
KR20240161977A (ko) 2022-02-23 2024-11-13 젠코어 인코포레이티드 항-CD28 x 항-PSMA 항체

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1159300A2 (en) 1999-02-12 2001-12-05 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
DK1673397T3 (da) 2003-07-02 2011-03-07 Univ Genova Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
ES2320374T3 (es) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
CA2669921A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
AU2011215750A1 (en) 2010-02-11 2012-08-23 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-CD200 antibodies
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
MA34619B1 (fr) * 2010-10-27 2013-10-02 Amgen Res Munich Gmbh Moyens et méthodes de traitement du lymphome b diffus à grandes cellules
US9758586B2 (en) * 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
DK3604339T3 (da) 2011-01-14 2021-04-12 Univ California Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
WO2013012414A1 (en) * 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SI2884999T2 (sl) * 2012-08-20 2026-01-30 Fred Hutchinson Cancer Center Metoda in sestavki za celično imunoterapijo
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AP2016009586A0 (en) * 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
AU2015353409B2 (en) * 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens

Also Published As

Publication number Publication date
WO2018014001A1 (en) 2018-01-18
JP2019532017A (ja) 2019-11-07
EP3484516A4 (en) 2020-03-18
AU2017297603A1 (en) 2019-02-14
US20190233534A1 (en) 2019-08-01
EP3484516A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
US20190233534A1 (en) Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2021286676B2 (en) Engineered immune cell expressing NK inhibitory molecule and use thereof
EP3240805B1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
EP4219693A1 (en) Chimeric antigen receptor targeting cd7 and use thereof
JP7649239B2 (ja) キメラ抗原受容体ファクトリおよびその使用方法
AU2019301070A1 (en) Fusion constructs and methods of using thereof
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
JP2019518424A (ja) 選択的タンパク質発現のための組成物および方法
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
WO2022056304A1 (en) Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
AU2021305234A1 (en) Fusion constructs and methods of using thereof
EP4491636A1 (en) Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof
WO2025059589A1 (en) Immune cell engaging molecules
US20230212286A1 (en) Antibodies specific for cd22 and uses thereof
WO2024140710A1 (zh) 一种特异性结合lilrb4的合成t细胞受体抗原受体及其应用
WO2023246574A1 (zh) 靶向gpc3的抗体及其用途
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
HK40077828A (en) Engineered immune cell expressing nk inhibitory molecule and use thereof
WO2020150513A1 (en) Methods to enhance the selectivity and effectiveness of cancer treatments
WO2026022767A1 (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231011